Patents Examined by David K O'Dell
  • Patent number: 11124505
    Abstract: The disclosure provides a process of making the compound of Formula I, and pharmaceutically acceptable salts thereof: and the process of making the intermediate of Formula III: wherein PG is as defined as set forth in the specification.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: September 21, 2021
    Assignee: Minoryx Therapeutics S.L.
    Inventors: Ana Maria García Collazo, Wolter Ten Hoeve, Johannes Nicolaas Koek, Johannes B. M. Rewinkel, Sander De Wilde
  • Patent number: 11117895
    Abstract: A process for producing crystals of a compound represented by the following formula (I): by crystallizing the compound from an aqueous solution containing the compound and an inorganic salt, such as sodium chloride. Such crystals can be subjected to lyophilization to provide a lyophilized composition having a desirable storage stability.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: September 14, 2021
    Assignee: MEIJI SEIKA PHARMA CO., LTD.
    Inventors: Takaya Ogawa, Takuya Yokoyama, Shusuke Furuyama, Masato Ichiki, Kenichi Fushihara
  • Patent number: 11111228
    Abstract: The present invention is related to an improved process for the preparation of Pomalidomide with higher yields and high purity. Particularly the present invention relates to form A preparation of Pomalidomide and its purification. wherein the present process doesn't involve use of dioxane solvent and avoids higher temperatures.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: September 7, 2021
    Assignee: Natco Pharma Limited
    Inventors: Durga Prasad Konakanchi, Buchappa Gongalla, Dharmendher Ragidi, Uma Naresh Babu Kotra, Kali Satya Bhujanga Rao Adibhatla, Venkaiah Chowdary Nannapaneni
  • Patent number: 11104676
    Abstract: Provided herein are compounds of the Formula I: and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, wherein R1, R2, R9, X1 and G are as defined herein, which are inhibitors of one or more TAM kinases and/or c-Met kinase, and are useful in the treatment and prevention of diseases which can be treated with a TAM kinase inhibitor and/or a c-Met kinase inhibitor.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: August 31, 2021
    Assignee: Array BioPharma Inc.
    Inventors: Ronald Jay Hinklin, Shelley Allen, Patrick Barbour, Adam Cook, Joshua Dahlke, John Gaudino, Ellen Laird, Oren T. McNulty, Qian Zhao
  • Patent number: 11098044
    Abstract: The present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salt, stereoisomers thereof, a pharmaceutical composition comprising the compound, and a method to treat or prevent neurodegenerative diseases using the compound.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: August 24, 2021
    Assignee: 1ST Biotherapeutics, Inc.
    Inventors: Jinhwa Lee, Suyeon Jo, Keonseung Lim, A Yeong Park, Jae Eun Kim, Misoon Kim, Seung Mook Lim
  • Patent number: 11090316
    Abstract: This disclosure relates to lipid disulfide prodrugs and in particular to lipid disulfide phosphodiester nucleosides and derivatives thereof, pharmaceutical compositions, and uses related thereto. According to one embodiment of the disclosure there is provided a compound of Formula I, or pharmaceutically acceptable salts or derivatives thereof, wherein substituents are disclosed herein.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: August 17, 2021
    Assignee: Emory University
    Inventors: Dennis Liotta, Kyle Giesler
  • Patent number: 11084810
    Abstract: This invention relates to novel (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles and their use as CB2 cannabinoid receptor agonists, pharmaceutical compositions containing the same, and their use for the treatment of CB2 receptor mediated disorders or conditions.
    Type: Grant
    Filed: January 22, 2020
    Date of Patent: August 10, 2021
    Assignee: Centrexion Therapeutics Corporation
    Inventors: Doris Riether, Florian Paul Christian Binder, Henri Doods, Stephan Georg Mueller, Janet Rachel Nicholson, Achim Sauer
  • Patent number: 11071729
    Abstract: The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: July 27, 2021
    Assignees: Addex Pharmaceuticals S.A., Janssen Pharmaceuticals, Inc.
    Inventors: Jose Maria Cid-Nunez, Andres Avelino Trabanco-Suarez, Gregor James MacDonald, Guillaume Albert Jacques Duvey, Terry Patrick Finn
  • Patent number: 11066390
    Abstract: Solid state forms of Ivosidenib, processes for preparation thereof, pharmaceutical compositions thereof, and uses thereof are disclosed.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: July 20, 2021
    Assignee: ASSIA CHEMICAL INDUSTRIES LTD.
    Inventors: Anantha Rajmohan Muthusamy, Amit Singh, Venkata Subbarao Yazali, Parven Kumar Luthra, Sanjay Lakhabhai Vasoya, Bhatu Tumba Patil, Amit Kumar Taneja, Naveen Chandra Srivastav, Rinku Singh, Vadivelan Rengasamy, Abhilash Tyagi
  • Patent number: 11066405
    Abstract: The present disclosure is directed to novel compounds of Formula I and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of cancer, including glioblastoma, bone cancer, head and neck cancer, melanoma, basal cell carcinoma, squamous cell carcinoma, adenocarcinoma, oral cancer, esophageal cancer, gastric cancer, intestinal cancer, colon cancer, bladder cancer, hepatocellular carcinoma, renal cell carcinoma, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, and prostate cancer. The compounds of the disclosure are selective antagonists of the EP4 receptor and useful treatment of various diseases that may be ameliorated with blockade of PGE2-mediated signaling.
    Type: Grant
    Filed: May 21, 2020
    Date of Patent: July 20, 2021
    Assignee: TEMPEST THERAPEUTICS, INC.
    Inventors: Yalda Bravo, Jason David Burch, Austin Chih-Yu Chen, Joe Fred Nagamizo
  • Patent number: 11058677
    Abstract: The present invention provides formulations, methods and kits for the treatment of dry eye diseases. In particular, stabilized pharmaceutical compositions comprising the compound of Formula 1 are described herein for a variety of uses including the treatment of dry eye syndrome. In one aspect, methods and ingredients for improving the stability of compositions of the compound of Formula 1 are described.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: July 13, 2021
    Assignee: Novartis AG
    Inventors: Mary Newman, William Hunke
  • Patent number: 11059818
    Abstract: The present invention provides compounds of Formula (I). wherein A and Z are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and may be useful for the treatment and/or prophylaxis of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: July 13, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Joanne M. Smallheer, Carol Hui Hu, Meriah Neissel Valente, Scott A. Shaw, Benjamin P. Vokits, Oz Scott Halpern
  • Patent number: 11053211
    Abstract: The present invention provides a novel process for the preparation of pomalidomide crystalline Form I. The present invention also provides a process for the purification of pomalidomide.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: July 6, 2021
    Assignee: HETERO RESEARCH FOUNDATION
    Inventors: Bandi Parthasaradhi Reddy, Kura Rathnakar Reddy, Dasari Muralidhara Reddy, Matta Ramakrishna Krishna Reddy, Bandi Vamsi Krishna
  • Patent number: 11040951
    Abstract: The technology described herein is directed to compounds which are substrates for ClbP, acting as fluorescent probes for ClbP activity. Further provided herein are methods for measuring ClbP activity, screening for ClbP inhibitors, detecting colibactin, and/or diagnosing cancer, which utilize the substrate compounds.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: June 22, 2021
    Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Matthew R. Volpe, Emily Patricia Balskus, Matthew Ryan Wilson
  • Patent number: 11028098
    Abstract: The present invention provide a compound having the structure: (structurally represented) wherein R1, R2, R3, R4, and R5 are each independently H, halogen, CF3 or C1-C4 alkyl; R6 is H, OH, or halogen; B is a substituted or unsubstituted heterobicycle, pyridazine, pyrazole, pyrazine, thiadiazole, or triazole, wherein the heterocycle is other than chloro substituted indole; and the pyrazole, when substituted, is substituted with other than trifluoromethyl, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 3, 2018
    Date of Patent: June 8, 2021
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Konstantin Petrukhin, Christopher Cioffi, Graham Johnson, Nicoleta Dobri, Emily Freeman, Ping Chen, Michael Conlon, Lei Zhu
  • Patent number: 11021458
    Abstract: Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.
    Type: Grant
    Filed: July 15, 2019
    Date of Patent: June 1, 2021
    Assignee: BioCryst Pharmaceuticals, Inc.
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Weihe Zhang, Peng-Cheng Lu, Minwan Wu, Wei Lv, Trung Xuan Nguyen, Zhao Dang, Venkat R. Chintareddy, V. Satish Kumar, Krishnan Raman
  • Patent number: 11008317
    Abstract: The present invention provides compounds of Formula (I); wherein the substituents are each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, and may be useful for the treatment and/or prophylaxis of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: May 18, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ellen K. Kick, Joanne M. Smallheer, Scott A. Shaw, Benjamin P. Vokits, Andrew K. Dilger, Charles G. Clark, Meriah Neissel Valente, Sutjano Jusuf, Nicholas R. Wurtz
  • Patent number: 11001583
    Abstract: Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.
    Type: Grant
    Filed: April 25, 2019
    Date of Patent: May 11, 2021
    Assignee: Vitae Pharmaceuticals, LLC
    Inventors: David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Stephen D. Lotesta, Andrew Marcus, Suresh B. Singh, Colin M. Tice, Jing Yuan, Wei Zhao, Linghang Zhuang
  • Patent number: 10988474
    Abstract: The present invention provides a compound, that is a 1-({halo-2-[(2-hydrocarbyl or substituted hydrocarbyl)oxy]phenyl}methyl)-(fused bicyclic nitrogen heteroaryl) carboxylic acid or an ester or sulfonamide thereof. The compound may be represented by the following formula Wherein R1, R2, R3, R4 A, X, W, Z and Y are as defined in the specification. The compounds may be administered to treat DP, FP, EP1, TP and/or EP4 receptor-mediated diseases or conditions.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: April 27, 2021
    Assignee: ALLERGAN, INC.
    Inventors: William R. Carling, Jose L. Martos, Jussi J. Kangasmetsa, Jenny W. Wang, David F. Woodward
  • Patent number: 10981867
    Abstract: The present invention provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by EBNA1 activity, such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and/or rheumatoid arthritis. The present invention further provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection and/or lytic EBV infection.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: April 20, 2021
    Assignee: The Wistar Institute of Anatomy and Biology
    Inventors: Troy E. Messick, Garry R. Smith, Allen B. Reitz, Paul M. Lieberman, Mark E. McDonnell, Yan Zhang, Marianne Carlsen, Shuai Chen